ClinicalTrials.gg
RecruitingNCT04843072BASELINEUpdated Oct 13, 2026

Balloon vs. Self Expanding Transcatheter Valve for Degenerated Bioprosthesis

An interventional study of EVOLUT R/PRO/PRO+/FX bioprosthesis and Edwards Sapien S3/Ultra bioprosthesis in Valve Heart Disease, sponsored by Erasmus Medical Center. Recruiting at 14 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.
Updated Oct 13, 2026Site recruiting status changedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 65 studies in Heart Valve Diseases with a site in Germany — 18 open to participants now, 24 under way, none of them phase 3. Heart Valve Diseases · Germany.

Planned enrollment
8th of 35
600 · median 180
Started
2021
with 7 others
No phase
32 of 65
4 open now
Primary completion
2028-06
later than 17 of 23 live
Registered
48th of 65
by date

Among the 65 studies in Heart Valve Diseases with a site in Germany, this one is the 8th largest by planned enrollment of the 35 interventional ones that give a count, is one of 8 that started in 2021, is one of 32 with no phase, reaches primary completion later than 17 of the 23 other live ones, and was the 48th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

18 of the 65 studies in Heart Valve Diseases with a site in Germany are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Heart Valve Diseases with a site in Germany, or all of them as a file.
02

Study summary

Transcatheter aortic valve implantation (TAVI) serves a growing spectrum of patients with symptomatic severe aortic stenosis (AS). Approximately 80% of surgical aortic valve replacements are performed using a bioprosthesis. Durability of surgical bioprostheses varies according to patient age at the time of implantation, prosthesis type and size, among other factors. TAVI has become an established treatment option for patients with a degenerated surgical aortic bioprosthesis. The time from index surgical aortic valve replacement (SAVR) to bioprosthetic valve degeneration is typically 8-10 years. TAVI in this setting has shown favorable outcomes. Balloon-expandable and self-expanding transcatheter heart valves (THVs) can both be used for the treatment of a degenerated surgical aortic bioprosthesis and have specific advantages and limitations. Valve-in-valve TAVI may be associated with coronary obstruction, THV migration, paravalvular regurgitation, and prosthesis-patient mismatch.

Objective:

To compare valve-in-valve TAVI with balloon-expandable SAPIEN/MYVAL THV series versus the self-expanding EVOLUT THV series. The primary analysis evaluates device success at 30 days in the primary cohort. Continued enrollment will additionally support a secondary comparison of the safety and efficacy of the SAPIEN and MYVAL THV series.

Study design: International multicenter randomized study with 1:1 randomization to TAVI with the EVOLUT THV series or the SAPIEN/MYVAL THV series.

Study population:

The primary cohort comprises 440 patients with a failing surgical aortic bioprosthesis (aortic stenosis with or without aortic regurgitation) selected for transfemoral TAVI by heart-team consensus. Enrollment of the primary cohort has been completed.

The continued-enrollment cohort comprises 160 additional patients and will increase the total study population to 600 patients, with a target distribution of 300 patients treated with the EVOLUT THV series, 150 with the SAPIEN THV series, and 150 with the MYVAL THV series.

Investigational intervention:

Transfemoral valve-in-valve TAVI with a balloon-expandable SAPIEN or MYVAL THV series or a self-expanding EVOLUT THV series.

Main study parameters/endpoints:

  1. Primary endpoint is device success at 30 days

    Defined by:

    • Absence of procedural mortality; AND
    • Technical success at exit from the procedure room defined as freedom from mortality, successful access, delivery of the device and retrieval of the delivery system, correct positioning of a single prosthetic heart valve into the proper anatomical location, and freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication; AND
    • Intended performance of the prosthetic heart valve (no severe prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \<3 m/s, Doppler velocity index ≥0.25, and no moderate or severe prosthetic valve regurgitation).

    Severe prosthesis-patient mismatch is defined as an indexed effective orifice area (EOAi) ≤0.65 cm²/m² (≤0.55 cm²/m² if BMI ≥30 kg/m²).

  2. Safety endpoint at 1 year defined by the composite of all-cause death, disabling stroke, rehospitalization for heart failure, or valve-related problems.
  3. Secondary objective is comparison of the safety and efficacy of the SAPIEN versus MYVAL THV series, including the incidence of moderate or severe prosthesis-patient mismatch.

The continued-enrollment cohort is designed to support this comparison.

03

Conditions studied

  • Valve Heart Disease

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Failing surgical aortic bioprosthesis requiring valve replacement and eligible for transfemoral TAVI with balloon expandable or self-expanding platform per heart team consensus based on multi-modality imaging assessment (including echocardiography and multidetector CT).
  • Written

Exclusion criteria

Exclusion Criteria:

  • Not eligible for Transfemoral TAVI with EVOLUT, SAPIEN or MYVAL THV series
  • Multi-valve defects requiring intervention
  • Clinically unstable and/or inotropic/vasopressor /mechanical support.
  • Known mural thrombus in the left ventricle
  • Presence of a mechanical aortic valve
  • History of recent (within 1 month) stroke or
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    EVOLUT R/PRO/PRO+/FX bioprosthesis

    Study subjects will receive a self-expanding valve from the EVOLUT THV series (EVOLUT R/PRO/PRO+/FX).

    Device: EVOLUT R/PRO/PRO+/FX bioprosthesis

  • Active comparator
    SAPIEN 3/Ultra or MYVAL/Octacor/Octapro bioprosthesis

    Study subjects will receive a balloon-expandable valve from either the SAPIEN THV series (SAPIEN 3, SAPIEN 3 Ultra) or the MYVAL THV series (Myval Octacor, Myval Octapro).

    Device: Edwards Sapien S3/Ultra bioprosthesis · Device: MYVAL/Octacor/Octapro bioprosthesis

Interventions

  • DeviceEVOLUT R/PRO/PRO+/FX bioprosthesis

    To compare EVOLUT R/PRO/PRO+/FX bioprosthesis versus Edwards SAPIEN 3/Ultra bioprosthesis or Myval/Octacor/ Octapro in failing surgical bioprostheses

  • DeviceEdwards Sapien S3/Ultra bioprosthesis

    Edwards Sapien S3/Ultra bioprosthesis

  • DeviceMYVAL/Octacor/Octapro bioprosthesis

    MYVAL/Octacor/Octapro bioprosthesis

06

What researchers measure

Primary outcomes

  1. Device success

    Defined by: * Absence of procedural mortality; AND * Technical success at exit from the procedure room defined as freedom from mortality, successful access, delivery of the device and retrieval of the delivery system, correct positioning of a single prosthetic heart valve into the proper anatomical location, and freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication; AND * Intended performance of the prosthetic heart valve (no severe prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \<3 m/s, Doppler velocity index ≥0.25, and no moderate or severe prosthetic valve regurgitation). Severe prosthesis-patient mismatch is defined as an indexed effective orifice area (EOAi) ≤0.65 cm²/m² (≤0.55 cm²/m² if BMI ≥30 kg/m²).

    Time frame: 30 days post transcatheter valve implantation

Secondary outcomes

  1. Composite of all-cause death, disabling stroke, rehospitalization for heart failure or valve related problems

    Safety endpoint

    Time frame: 1 year post transcatheter valve implantation

  2. Moderate or severe prosthesis-patient mismatch

    Moderate or severe prosthesis-patient mismatch is defined as EOAi ≤0.85 cm²/m² (≤0.70 cm²/m² if BMI ≥30 kg/m²). This endpoint will be compared between patients treated with the SAPIEN and MYVAL THV series.

    Time frame: 30 days post transcatheter valve implantation

07

Study locations

8 of 14 sites recruiting
  • Cedars Sinai
    Los Angeles, California 90048, United States
    Recruiting
    • Raj Makkar, MD · Contact
    • Raj Makkar, MD · Principal investigator
  • Vienna General Hospital
    Vienna, Austria
    Recruiting
    • Christian Hengstenberg, MD, PhD · Contact
    • Christian Hengstenberg, MD, PhD · Principal investigator
  • St Paul's and Vancouver General Hospital
    Vancouver, Canada
    Not yet recruiting
    • John Webb, MD · Contact
    • John Webb, MD · Principal investigator
    • David Wood, MD · Principal investigator
  • Rigshospitalet
    Copenhagen, Denmark
    Not yet recruiting
    • Lars Sondergaard, MD · Contact
    • Lars Sondergaard, MD · Principal investigator
  • Institut Cœur Poumon
    Lille, France
    Recruiting
    • Eric Van Belle, MD · Contact
    • Eric Van Belle, MD · Principal investigator
  • Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany
    Düsseldorf, Germany
    Recruiting
    • Verena Veulemans, MD PhD · Contact
  • University Hospital Mainz
    Mainz, Germany
    Not yet recruiting
    • Stephan Von Bardeleben, MD · Contact
    • Stephan Von Bardeleben, MD · Principal investigator
  • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece
    Athens, Greece
    Recruiting
    • Ioannis Iakovou, MD PhD · Contact
  • Interventional Cardiology Unit, Cardiovascular Department, Fondazione Poliambulanza Institute, Brescia, Italy
    Brescia, Italy
    Recruiting
    • Diego Maffeo, MD PhD · Contact
  • University Hospital of Padova
    Padua, Italy
    Not yet recruiting
    • Giusepe Tarantini, MD · Contact
    • Giusepe Tarantini, MD · Principal investigator
  • Erasmus Medical Centre
    Rotterdam, 3015 GD, Netherlands
    Recruiting
  • Centro Hospitalar de Lisboa Ocidental
    Lisbon, Portugal
    Recruiting
    • Rui Teles, MD · Contact
    • Rui Teles, MD · Principal investigator
  • Inselspital, University Hospital
    Bern, Switzerland
    Not yet recruiting
    • Thomas Pilgrim, MD · Contact
    • Thomas Pilgrim · Principal investigator
  • Leeds Teaching Hospitals
    Leeds, United Kingdom
    Not yet recruiting
    • Daniel Blackman, MD · Contact
    • Daniel Blackman, MD · Principal investigator
08

References and documents

Publications

  • Nuis RJ, van Belle E, Teles R, Blackman D, Veulemans V, Santos IA, Pilgrim T, Tarantini G, Saia F, Iakovou I, Mascherbauer J, Vincent F, Geleijnse M, Sathananthan J, Wood D, Makkar R, Van Mieghem NM; BASELINE Investigators. BAlloon expandable vs. SElf expanding transcatheter vaLve for degenerated bioprosthesIs: design and rationale of the BASELINE trial. Am Heart J. 2023 Feb;256:139-147. doi: 10.1016/j.ahj.2022.11.013. Epub 2022 Nov 19. PubMed 36410441 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jun 2028, 85 months after the start.

Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 85 months is above that.

Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion May 2026 → Jun 2028 and completion May 2026 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2021
First posted
Apr 13, 2021
StartActual
May 1, 2021
Primary completionEst.
Jun 1, 2028was May 2026
CompletionEst.
May 1, 2029was May 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Cedars Sinai · Los Angeles, United StatesNot yet recruiting→Recruiting
  • Vienna General Hospital · Vienna, AustriaNot yet recruiting→Recruiting
  • Institut Cœur Poumon · Lille, FranceNot yet recruiting→Recruiting
  • Centro Hospitalar de Lisboa Ocidental · Lisbon, PortugalNot yet recruiting→Recruiting
Show site
  • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece · Athens, Greece
Show 1 removed
  • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece · Athen, Greece
Oct 13, 2026
Primary completion
May 1, 2026→Jun 1, 2028
Oct 13, 2026
Study completion
May 1, 2026→May 1, 2029
Oct 13, 2026
Enrollment
400→600
Oct 13, 2026
Eligibility
Minimum age 65 Years→18 Years; 1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAge ≥ 6518 years
Exclusion criteria
  • ChangedBefore Not eligible for Transfemoral TAVI with SAPIEN-3 / Ultra and Evolut R/ProNow Not eligible for Transfemoral TAVI with EVOLUT, SAPIEN or MYVAL THV series
Oct 13, 2026
Interventions
Added Device: EVOLUT R/PRO/PRO+/FX bioprosthesis·Device: MYVAL/Octacor/Octapro bioprosthesis; removed Device: Evolut R/PRO bioprosthesis. Arm changed Evolut R/Pro bioprosthesis→EVOLUT R/PRO/PRO+/FX bioprosthesis. Arms added: SAPIEN 3/Ultra or MYVAL/Octacor/Octapro bioprosthesis; arms removed: Edwards Sapien S3/Ultra bioprosthesis
Oct 13, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionDevice success: how it is measured was reworded
Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 36410441 ↗
Oct 13, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedModerate or severe prosthesis-patient mismatchTime frame: 30 days post transcatheter valve implantation
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 36410441 ↗
    1 site added, 1 site removed. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Cedars Sinai · Los Angeles, United StatesNot yet recruiting→Recruiting
    • Vienna General Hospital · Vienna, AustriaNot yet recruiting→Recruiting
    • Institut Cœur Poumon · Lille, FranceNot yet recruiting→Recruiting
    • Centro Hospitalar de Lisboa Ocidental · Lisbon, PortugalNot yet recruiting→Recruiting
    Show site
    • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece · Athens, Greece
    Show 1 removed
    • Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece · Athen, Greece
    Primary completion May 1, 2026→Jun 1, 2028
    Study completion May 1, 2026→May 1, 2029
    Enrollment 400→600
    Eligibility Minimum age 65 Years→18 Years; 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge ≥ 6518 years
    Exclusion criteria
    • ChangedBefore Not eligible for Transfemoral TAVI with SAPIEN-3 / Ultra and Evolut R/ProNow Not eligible for Transfemoral TAVI with EVOLUT, SAPIEN or MYVAL THV series
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionDevice success: how it is measured was reworded
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedModerate or severe prosthesis-patient mismatchTime frame: 30 days post transcatheter valve implantation
    Interventions Added Device: EVOLUT R/PRO/PRO+/FX bioprosthesis·Device: MYVAL/Octacor/Octapro bioprosthesis; removed Device: Evolut R/PRO bioprosthesis. Arm changed Evolut R/Pro bioprosthesis→EVOLUT R/PRO/PRO+/FX bioprosthesis. Arms added: SAPIEN 3/Ultra or MYVAL/Octacor/Octapro bioprosthesis; arms removed: Edwards Sapien S3/Ultra bioprosthesis
    + 4 other changes: verification date, responsible party, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04843072
Responsible party
Rutger-Jan Nuis (Dr., Erasmus Medical Center) — Principal investigator
First posted
Apr 13, 2021
Start date
May 1, 2021
Primary completion
Jun 1, 2028 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Rutger-Jan Nuis, MD, PhD
Contact
r.nuis@erasmusmc.nl
+31614858291
Nicolas Van Mieghem, MD, PhD
principal investigator · Erasmus Medical Centre
Rutger-Jan Nuis, MD, PhD
principal investigator · Erasmus Medical Centre

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion